CB10-277
CB10-277 is a synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties. Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups.
1: Bleehen NM, Calvert AH, Lee SM, Harper P, Kaye SB, Judson I, Brampton M. A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma. Br J Cancer. 1994 Oct;70(4):775-7. PubMed PMID: 7917939; PubMed Central PMCID: PMC2033397.
2: Lee SM, O'Connor PJ, Thatcher N, Crowther D, Margison GP, Cooper DP. Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes. Cancer Res. 1994 Aug 1;54(15):4072-6. PubMed PMID: 8033139.
3: Foster BJ, Newell DR, Gumbrell LA, Jenns KE, Calvert AH. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer. 1993 Feb;67(2):369-73. PubMed PMID: 8431368; PubMed Central PMCID: PMC1968159.
4: Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, Calvert AH. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer. 1993 Feb;67(2):362-8. PubMed PMID: 8431367; PubMed Central PMCID: PMC1968184.
5: Lee SM, Thatcher N, Crowther D, Margison GP. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol. 1992;31(3):240-6. PubMed PMID: 1464162.
2: Lee SM, O'Connor PJ, Thatcher N, Crowther D, Margison GP, Cooper DP. Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes. Cancer Res. 1994 Aug 1;54(15):4072-6. PubMed PMID: 8033139.
3: Foster BJ, Newell DR, Gumbrell LA, Jenns KE, Calvert AH. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer. 1993 Feb;67(2):369-73. PubMed PMID: 8431368; PubMed Central PMCID: PMC1968159.
4: Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, Calvert AH. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer. 1993 Feb;67(2):362-8. PubMed PMID: 8431367; PubMed Central PMCID: PMC1968184.
5: Lee SM, Thatcher N, Crowther D, Margison GP. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol. 1992;31(3):240-6. PubMed PMID: 1464162.
| Chemical | |
|---|---|
| CAS Num | 7203-91-0 |
| Chemical Formula | C9H11N3O2 |
| Molecular Weight | 193.2 |
| IUPAC Chemical Name | (E)-4-(3,3-dimethyltriaz-1-en-1-yl)benzoic acid |
| Exact Mass | 193.08513 |
| Elemental Analysis | C, 55.95; H, 5.74; N, 21.75; O, 16.56 |
| Synonym | CB10277; CB10-277; CB10 277; 1pcarboxy33dimethylphenyltriazine. |
| Solubility | Soluble in DMSO, not in water |
| SMILES Code | O=C(O)C1=CC=C(/N=N/N(C)C)C=C1 |
| Biological | |
| Targets and Effects | N/A |
| Pathways | alkylating agent |
| Physical | |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Shelf Life | >5 years if stored properly |
Mailing Address
Anba Pharma Company
3-H Gill Street, Suite 300
Woburn, MA 01801
United State
Our Contact Info.
Tel: 1+610-883-0668
Email: sales@AnbaPharma.com